Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Conditions
Keywords
sphingolipids, hepatic steatosis, non-alcoholic fatty liver disease, macrovascular complications, insulin resistance, microvasclar complications, NAFLD
Brief summary
Sphingolipids are associated with metabolic diseases. Distribution of plasma sphingolipids in type 1 and type 2 diabetes has never been studied. The objective of the CERADIAB study is to compare plasma sphingoliplids concentrations in type 1 and type 2 diabetic patients.
Detailed description
Sphingolipids represent a major class of lipids that are structural and signaling molecules. Major bioactive sphingolipids include ceramide, dihydroceramide, sphingosine, sphingosine-1-phosphate and sphingomyelin. Sphingoliplids are involved in development of various chronic metabolic diseases. Some ceramides species are implicated in pancreatic β-cell apoptosis and in insulin resistance in muscle, fat and liver. Some studies have shown association between inhibition of ceramide synthesis, insulin sensibility and lower hepatic steatosis. The deposition of hepatic lipids, especially triacylglycerol, defines the development of hepatic steatosis. However, sphingolipids appear to play an important role in non-alcoholic fatty liver disease (NAFLD) and in its progression. Changes in plasma shingolipids concentrations may also contribute to the pathogenesis in cardiovascular disease and atherosclerosis. Distribution of plasma sphingolipids concentrations in type 1 and type 2 diabetes has poorly been studied. The objective of the CERADIAB study is to compare plasma sphingoliplids concentrations in type 1 and type 2 diabetic patients.
Interventions
OTHERdosing of sphingolipids
\- Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine
Sponsors
Groupe Hospitalier Pitie-Salpetriere
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* type 1 or 2 diabetes
Exclusion criteria
* atypical diabetes * family dyslipidemia * nonmetabolic hepatopathy * severe renal failure * corticosteroid or immunosuppressive therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of plasma total ceramides concentration in type 2 diabetic patients versus type 1 diabetic patients. | Samples taken in 1 single time in the morning, patients fast for 12 hours, on 1 single day | Three-hundred microlitres of plasma were used to quantify dihydroceramides, ceramides, sphingomyelins and sphingosine content. The lipid subspecies were extracted and analysed by Liquid Chromatography Mass Spectrometry (LC-MS/MS), at the Lipidomic Core Facility of the University of Bourgogne (Dijon, France). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| - - Comparison of plasma total sphingomyelins concentration in type 2 diabetic patients versus type 1 diabetic patients. | Samples taken in 1 single time in the morning, patients fast for 12 hours, on 1 single day | Three-hundred microlitres of plasma were used to quantify dihydroceramides, ceramides, sphingomyelins and sphingosine content. The lipid subspecies were extracted and analysed by Liquid Chromatography Mass Spectrometry (LC-MS/MS), at the Lipidomic Core Facility of the University of Bourgogne (Dijon, France). |
| - Comparison of plasma total sphingosine concentration in type 2 diabetic patients versus type 1 diabetic patients. | Samples taken in 1 single time in the morning, patients fast for 12 hours, on 1 single day | Three-hundred microlitres of plasma were used to quantify dihydroceramides, ceramides, sphingomyelins and sphingosine content. The lipid subspecies were extracted and analysed by Liquid Chromatography Mass Spectrometry (LC-MS/MS), at the Lipidomic Core Facility of the University of Bourgogne (Dijon, France). |
| - Comparison of plasma ceramide species (C16, C18, C20, C22, C23, C24, C24:1, C26:1, C26:2 ceramides) concentration in type 2 diabetic patients versus type 1 diabetic patients. | Samples taken in 1 single time in the morning, patients fast for 12 hours, on 1 single day | Three-hundred microlitres of plasma were used to quantify dihydroceramides, ceramides, sphingomyelins and sphingosine content. The lipid subspecies were extracted and analysed by Liquid Chromatography Mass Spectrometry (LC-MS/MS), at the Lipidomic Core Facility of the University of Bourgogne (Dijon, France). |
| - Comparison of plasma dihydroceramide species (C18/16, C18/18, C18/20, C18/22, C18/23, C18/24, C18/24:1, C18/26:1, C18/26:2 dihydroceramides) concentration in type 2 diabetic patients versus type 1 diabetic patients. | Samples taken in 1 single time in the morning, patients fast for 12 hours, on 1 single day | Three-hundred microlitres of plasma were used to quantify dihydroceramides, ceramides, sphingomyelins and sphingosine content. The lipid subspecies were extracted and analysed by Liquid Chromatography Mass Spectrometry (LC-MS/MS), at the Lipidomic Core Facility of the University of Bourgogne (Dijon, France). |
| - Comparison of plasma total dihydroceramides concentration in type 2 diabetic patients versus type 1 diabetic patients. | Samples taken in 1 single time in the morning, patients fast for 12 hours, on 1 single day | Three-hundred microlitres of plasma were used to quantify dihydroceramides, ceramides, sphingomyelins and sphingosine content. The lipid subspecies were extracted and analysed by Liquid Chromatography Mass Spectrometry (LC-MS/MS), at the Lipidomic Core Facility of the University of Bourgogne (Dijon, France). |
| - Correlation between sphingolipids species concentrations and insulin resistance (HOMA-IR) | Samples taken in 1 single time in the morning, patients fast for 12 hours, on 1 single day | Three-hundred microlitres of plasma were used to quantify dihydroceramides, ceramides, sphingomyelins and sphingosine content. The lipid subspecies were extracted and analysed by Liquid Chromatography Mass Spectrometry (LC-MS/MS), at the Lipidomic Core Facility of the University of Bourgogne (Dijon, France). |
| - Correlation between sphingolipids species concentrations and microvascular complications (history of retinopathy, nephropathy and neuropathy) | Samples taken in 1 single time in the morning, patients fast for 12 hours, on 1 single day | Three-hundred microlitres of plasma were used to quantify dihydroceramides, ceramides, sphingomyelins and sphingosine content. The lipid subspecies were extracted and analysed by Liquid Chromatography Mass Spectrometry (LC-MS/MS), at the Lipidomic Core Facility of the University of Bourgogne (Dijon, France). |
| - Correlation between sphingolipids species concentrations and macrovascular complications (cardiovascular disease history) | Samples taken in 1 single time in the morning, patients fast for 12 hours, on 1 single day | Three-hundred microlitres of plasma were used to quantify dihydroceramides, ceramides, sphingomyelins and sphingosine content. The lipid subspecies were extracted and analysed by Liquid Chromatography Mass Spectrometry (LC-MS/MS), at the Lipidomic Core Facility of the University of Bourgogne (Dijon, France). |
| - Correlation between sphingolipids species concentrations and NAFLD biomarkers (steatotest, NASHtest and fibrotest) | Samples taken in 1 single time in the morning, patients fast for 12 hours, on 1 single day | Three-hundred microlitres of plasma were used to quantify dihydroceramides, ceramides, sphingomyelins and sphingosine content. The lipid subspecies were extracted and analysed by Liquid Chromatography Mass Spectrometry (LC-MS/MS), at the Lipidomic Core Facility of the University of Bourgogne (Dijon, France). |
Countries
France
Outcome results
None listed